Capital Fund Management S.A. Boosts Stock Holdings in Medpace Holdings, Inc. $MEDP

Capital Fund Management S.A. lifted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 129.5% in the 3rd quarter, Holdings Channel.com reports. The fund owned 32,412 shares of the company’s stock after buying an additional 18,287 shares during the quarter. Capital Fund Management S.A.’s holdings in Medpace were worth $16,665,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in MEDP. Quent Capital LLC bought a new position in Medpace in the 3rd quarter valued at approximately $25,000. Optiver Holding B.V. bought a new stake in shares of Medpace in the 3rd quarter worth $27,000. Geneos Wealth Management Inc. raised its stake in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Employees Retirement System of Texas purchased a new position in shares of Medpace in the second quarter worth $36,000. Finally, Root Financial Partners LLC bought a new position in shares of Medpace during the third quarter valued at $38,000. 77.98% of the stock is owned by institutional investors.

Medpace Price Performance

Shares of Medpace stock opened at $477.72 on Thursday. The company’s fifty day simple moving average is $528.39 and its 200-day simple moving average is $539.24. The stock has a market capitalization of $13.56 billion, a PE ratio of 31.22, a P/E/G ratio of 2.24 and a beta of 1.44. Medpace Holdings, Inc. has a 1-year low of $250.05 and a 1-year high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The firm had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. During the same period in the prior year, the business posted $3.67 EPS. Medpace’s revenue was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on MEDP. TD Cowen raised Medpace from a “sell” rating to a “hold” rating and dropped their price objective for the company from $462.00 to $419.00 in a research report on Wednesday, February 18th. Mizuho set a $582.00 target price on shares of Medpace in a research note on Wednesday, February 11th. Truist Financial dropped their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a report on Wednesday, February 11th. BMO Capital Markets reiterated a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Finally, Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective for the company in a report on Friday, February 13th. Five research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $486.67.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.